Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Cohen, Stanley; M. Levy, Robert; Keller, Michael; Boling, E; Emkey, Ronald; Greenwald, Maria; M. Zizic, Thomas; Wallach, Stanley; Lea Sewell, K.; P. Lukert, Barbara; W. Axelrod, Douglas; Chines, Arkadi

doi:10.1002/1529-0131(199911)42:11<2309::aid-anr8>3.0.co;2-k

Public

Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Published in Arthritis & Rheumatism • Nov 1, 1999

Authors:

Stanley Cohen

Robert M. Levy

Michael Keller

Abstract

OBJECTIVE: Risedronate, a new pyridinyl bisphosphonate, is a potent antiresorptive bone agent. This study examines the safety and efficacy of daily, oral risedronate therapy for the prevention of corticosteroid-induced bone loss. METHODS: This multicenter, randomized, double-blind, placebo-controlle...

Subject

Medicine

Placebo

Osteoporosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!